

# Ellen L Weisberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5114721/publications.pdf>

Version: 2024-02-01

74  
papers

5,754  
citations

196777

29  
h-index

104191

69  
g-index

75  
all docs

75  
docs citations

75  
times ranked

7093  
citing authors

#	ARTICLE	IF	CITATIONS
1	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. <i>Leukemia</i> , 2022, 36, 210-220.	3.3	12
2	Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. <i>Leukemia</i> , 2022, 36, 1048-1057.	3.3	5
3	BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	11
4	Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 605-609.	1.7	3
5	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9.	0.6	5
6	Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). <i>British Journal of Cancer</i> , 2021, 125, 582-592.	2.9	4
7	Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 334.	7.1	6
8	Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). <i>Cancers</i> , 2021, 13, 7.	1.7	13
9	HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance. <i>Blood Science</i> , 2021, 3, 151-153.	0.4	1
10	Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. <i>Leukemia</i> , 2020, 34, 625-629.	3.3	9
11	Repurposing of Kinase Inhibitors for Treatment of COVID-19. <i>Pharmaceutical Research</i> , 2020, 37, 167.	1.7	102
12	Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. <i>Scientific Reports</i> , 2020, 10, 5324.	1.6	69
13	Current therapies under investigation for COVID-19: potential COVID-19 treatments. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 483-489.	0.7	6
14	Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2968-2980.	1.6	16
15	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2145-2156.	1.6	2
16	Inhibition of the deubiquitinase USP10 induces degradation of SYK. <i>British Journal of Cancer</i> , 2020, 122, 1175-1184.	2.9	19
17	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. <i>British Journal of Haematology</i> , 2019, 187, 488-501.	1.2	30
18	A non-covalent inhibitor XMU-003 overrides ibrutinib-resistant C481S mutation in B-cell malignancies. <i>British Journal of Pharmacology</i> , 2019, 176, 4491-4509.	2.7	17

#	ARTICLE	IF	CITATIONS
19	Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 875-892.	2.9	20
20	Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 175-182.	1.0	15
21	Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies. <i>Biochemistry</i> , 2018, 57, 477-478.	1.2	15
22	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degradator. <i>Cell Chemical Biology</i> , 2018, 25, 88-99.e6.	2.5	313
23	Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 137, 545-557.	2.6	16
24	Structure-guided development of covalent TAK1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 838-846.	1.4	28
25	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1320-1328.	1.4	17
26	Inhibition of USP10 induces degradation of oncogenic FLT3. <i>Nature Chemical Biology</i> , 2017, 13, 1207-1215.	3.9	89
27	Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. <i>Cell Chemical Biology</i> , 2017, 24, 1490-1500.e11.	2.5	149
28	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. <i>Oncotarget</i> , 2017, 8, 67639-67650.	0.8	26
29	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. <i>Oncotarget</i> , 2017, 8, 52026-52044.	0.8	19
30	Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. <i>Oncotarget</i> , 2017, 8, 109973-109984.	0.8	19
31	Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. <i>Oncotarget</i> , 2016, 7, 29131-29142.	0.8	21
32	Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 476-481.	1.3	17
33	Simultaneous inhibition of Vps34 kinase would enhance PI3K $\gamma$ inhibitor cytotoxicity in the B-cell malignancies. <i>Oncotarget</i> , 2016, 7, 53515-53525.	0.8	19
34	Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. <i>Oncotarget</i> , 2016, 7, 69760-69769.	0.8	41
35	Characterization of selective and potent PI3K $\gamma$ inhibitor (PI3KD-IN-015) for B-Cell malignancies. <i>Oncotarget</i> , 2016, 7, 32641-32651.	0.8	7
36	Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia. <i>Blood</i> , 2016, 128, 524-524.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. <i>Blood</i> , 2015, 125, 3133-3143.	0.6	23
38	Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2249-2259.	1.9	53
39	Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1299-1308.	0.4	15
40	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. <i>Leukemia</i> , 2015, 29, 27-37.	3.3	51
41	Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. <i>Oncotarget</i> , 2015, 6, 31313-31322.	0.8	38
42	Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3694-3694.	0.6	0
43	Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. <i>Archives of Toxicology</i> , 2014, 88, 2233-2242.	1.9	6
44	Upregulation of IGF1R by Mutant <i>RAS</i> in Leukemia and Potentiation of <i>RAS</i> Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. <i>Clinical Cancer Research</i> , 2014, 20, 5483-5495.	3.2	16
45	Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells. <i>PLoS ONE</i> , 2013, 8, e56473.	1.1	38
46	Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells. <i>Blood</i> , 2013, 122, 1479-1479.	0.6	2
47	An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFR $\pm$ and kit. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4579-4584.	1.0	12
48	Development of "DFG-out"™ inhibitors of gatekeeper mutant kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5297-5302.	1.0	10
49	BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production. <i>Blood</i> , 2012, 120, 1673-1673.	0.6	0
50	Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells. <i>PLoS ONE</i> , 2011, 6, e25351.	1.1	42
51	Potentiation of the Effects of Nilotinib by Combination with Plerixafor in a Mouse Model of BCR-ABL-Positive Residual Disease. <i>Blood</i> , 2011, 118, 2737-2737.	0.6	0
52	Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR $\pm$ , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. <i>Blood</i> , 2010, 115, 4206-4216.	0.6	61
53	Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2468-2477.	1.9	15
54	Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. <i>Genes and Cancer</i> , 2010, 1, 1021-1032.	0.6	33

#	ARTICLE	IF	CITATIONS
55	FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resistance Updates, 2009, 12, 81-89.	6.5	95
56	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. Blood, 2009, 114, 1722-1722.	0.6	0
57	Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Molecular Cancer Therapeutics, 2008, 7, 1121-1129.	1.9	65
58	Potential of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL and mutant FLT3-expressing cells. Blood, 2008, 111, 3723-3734.	0.6	81
59	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood, 2008, 112, 5161-5170.	0.6	29
60	Potential of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Molecular Cancer Therapeutics, 2007, 6, 1951-1961.	1.9	78
61	Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood, 2007, 109, 2112-2120.	0.6	98
62	Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity. Gastroenterology, 2006, 131, 1734-1742.	0.6	93
63	Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7, 129-141.	7.7	1,387
64	Simultaneous Administration of AMN107 and Imatinib in the Treatment of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia.. Blood, 2005, 106, 694-694.	0.6	7
65	Novel Hydroxamic Acid-Derived HDAC Inhibitor LBH589 Potently Activates Intrinsic and Extrinsic Apoptotic Pathways, and Induces Tubulin Hyperacetylation in Multiple Myeloma.. Blood, 2005, 106, 1578-1578.	0.6	1
66	Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood, 2004, 104, 1855-1858.	0.6	80
67	AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.. Blood, 2004, 104, 551-551.	0.6	2
68	PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR $\beta$ -induced myeloproliferative disease. Cancer Cell, 2003, 3, 459-469.	7.7	223
69	Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resistance Updates, 2003, 6, 231-238.	6.5	84
70	Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell, 2002, 1, 433-443.	7.7	574
71	ARG tyrosine kinase activity is inhibited by STI571. Blood, 2001, 97, 2440-2448.	0.6	246
72	Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL transformed hematopoietic cell lines. Blood, 2000, 95, 3498-3505.	0.6	374

#	ARTICLE	IF	CITATIONS
73	Smad4 and FAST-1 in the assembly of activin-responsive factor. <i>Nature</i> , 1997, 389, 85-89.	13.7	534
74	Tensin: A potential link between the cytoskeleton and signal transduction. <i>BioEssays</i> , 1994, 16, 817-823.	1.2	125